HLA-B*5701 and abacavir hypersensitivity (multiple letters)

Pharmacogenetics

Volumn 14, Issue 11, 2004, Pages 783-784

  Watson, Maria E ^a,b,c   Pimenta, Jeanne M ^a,b,c   Spreen, William R ^a,b,c   Hernandez, Jaime E ^a,b,c   Hughes, Dyfrig ^d   Park, B Kevin ^d   Pirmohamed, Munir ^d  

^a GLAXOSMITHKLINE   (United States)

^b GlaxoSmithKline ^*

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; HLA B ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE;

AUSTRALIA; CASE FINDING; CAUCASIAN; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG REEXPOSURE; DRUG WITHDRAWAL; ETHNIC GROUP; GENETIC SCREENING; GENOTYPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; HYPERSENSITIVITY REACTION; INCIDENCE; LABORATORY DIAGNOSIS; LETTER; MEDICAL LITERATURE; METHODOLOGY; PATHOGENESIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION; RETROSPECTIVE STUDY; RISK MANAGEMENT; UNITED KINGDOM; GENETICS; NOTE;

DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HLA-B ANTIGENS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 21644437422     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200411000-00011     Document Type: Letter

References (0)